vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $20.3M, roughly 1.8× Ispire Technology Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -32.5%, a 28.9% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -17.8%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

GYRE vs ISPR — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.8× larger
GYRE
$37.2M
$20.3M
ISPR
Growing faster (revenue YoY)
GYRE
GYRE
+84.9% gap
GYRE
33.4%
-51.5%
ISPR
Higher net margin
GYRE
GYRE
28.9% more per $
GYRE
-3.7%
-32.5%
ISPR
More free cash flow
ISPR
ISPR
$1.7M more FCF
ISPR
$-4.0M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
GYRE
GYRE
ISPR
ISPR
Revenue
$37.2M
$20.3M
Net Profit
$-1.4M
$-6.6M
Gross Margin
95.3%
17.1%
Operating Margin
0.3%
-33.9%
Net Margin
-3.7%
-32.5%
Revenue YoY
33.4%
-51.5%
Net Profit YoY
-340.1%
17.4%
EPS (diluted)
$-0.01
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
ISPR
ISPR
Q4 25
$37.2M
$20.3M
Q3 25
$30.6M
$30.4M
Q2 25
$26.8M
$20.1M
Q1 25
$22.1M
$26.2M
Q4 24
$27.9M
$41.8M
Q3 24
$25.5M
$39.3M
Q2 24
$25.2M
$37.3M
Q1 24
$27.2M
$30.0M
Net Profit
GYRE
GYRE
ISPR
ISPR
Q4 25
$-1.4M
$-6.6M
Q3 25
$5.9M
$-3.3M
Q2 25
$1.6M
$-14.8M
Q1 25
$3.7M
$-10.9M
Q4 24
$569.0K
$-8.0M
Q3 24
$2.9M
$-5.6M
Q2 24
$4.5M
$-3.5M
Q1 24
$9.9M
$-5.9M
Gross Margin
GYRE
GYRE
ISPR
ISPR
Q4 25
95.3%
17.1%
Q3 25
94.7%
17.0%
Q2 25
95.7%
12.3%
Q1 25
95.9%
18.2%
Q4 24
95.8%
18.5%
Q3 24
96.2%
19.5%
Q2 24
96.9%
28.3%
Q1 24
96.4%
20.4%
Operating Margin
GYRE
GYRE
ISPR
ISPR
Q4 25
0.3%
-33.9%
Q3 25
22.7%
-8.9%
Q2 25
8.1%
-72.7%
Q1 25
10.3%
-40.4%
Q4 24
2.4%
-17.6%
Q3 24
16.6%
-13.4%
Q2 24
12.7%
-9.2%
Q1 24
29.7%
-18.8%
Net Margin
GYRE
GYRE
ISPR
ISPR
Q4 25
-3.7%
-32.5%
Q3 25
19.4%
-10.7%
Q2 25
5.9%
-73.4%
Q1 25
16.9%
-41.5%
Q4 24
2.0%
-19.1%
Q3 24
11.2%
-14.2%
Q2 24
18.0%
-9.4%
Q1 24
36.6%
-19.7%
EPS (diluted)
GYRE
GYRE
ISPR
ISPR
Q4 25
$-0.01
$-0.12
Q3 25
$0.03
$-0.06
Q2 25
$0.00
$-0.26
Q1 25
$0.00
$-0.19
Q4 24
$0.00
$-0.14
Q3 24
$0.01
$-0.10
Q2 24
$0.01
$-0.07
Q1 24
$0.03
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$52.4M
$17.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$-7.7M
Total Assets
$166.1M
$84.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
ISPR
ISPR
Q4 25
$52.4M
$17.6M
Q3 25
$60.0M
$22.7M
Q2 25
$54.4M
$24.4M
Q1 25
$29.9M
$23.5M
Q4 24
$26.7M
$34.4M
Q3 24
$25.1M
$37.7M
Q2 24
$25.1M
$35.1M
Q1 24
$37.4M
$39.5M
Stockholders' Equity
GYRE
GYRE
ISPR
ISPR
Q4 25
$106.0M
$-7.7M
Q3 25
$101.9M
$-1.8M
Q2 25
$92.0M
$604.7K
Q1 25
$68.1M
$14.8M
Q4 24
$63.3M
$24.2M
Q3 24
$63.2M
$30.7M
Q2 24
$60.4M
$34.5M
Q1 24
$56.6M
$35.9M
Total Assets
GYRE
GYRE
ISPR
ISPR
Q4 25
$166.1M
$84.4M
Q3 25
$159.4M
$96.4M
Q2 25
$152.6M
$102.2M
Q1 25
$129.8M
$115.7M
Q4 24
$125.4M
$132.0M
Q3 24
$125.2M
$129.0M
Q2 24
$120.9M
$122.6M
Q1 24
$122.0M
$108.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
ISPR
ISPR
Operating Cash FlowLast quarter
$-5.6M
$-4.0M
Free Cash FlowOCF − Capex
$-5.8M
$-4.0M
FCF MarginFCF / Revenue
-15.5%
-19.9%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
ISPR
ISPR
Q4 25
$-5.6M
$-4.0M
Q3 25
$4.7M
$-1.2M
Q2 25
$2.1M
$4.7M
Q1 25
$-129.0K
$-12.5M
Q4 24
$-2.8M
$-3.2M
Q3 24
$1.7M
$3.6M
Q2 24
$-5.5M
$-1.4M
Q1 24
$2.9M
$3.4M
Free Cash Flow
GYRE
GYRE
ISPR
ISPR
Q4 25
$-5.8M
$-4.0M
Q3 25
$4.0M
$-1.2M
Q2 25
$1.8M
$3.7M
Q1 25
$-251.0K
$-12.7M
Q4 24
$-2.8M
$-3.2M
Q3 24
$1.0M
$3.3M
Q2 24
$-6.9M
$-2.2M
Q1 24
$2.7M
$3.3M
FCF Margin
GYRE
GYRE
ISPR
ISPR
Q4 25
-15.5%
-19.9%
Q3 25
13.1%
-3.9%
Q2 25
6.8%
18.6%
Q1 25
-1.1%
-48.4%
Q4 24
-10.1%
-7.7%
Q3 24
4.1%
8.5%
Q2 24
-27.5%
-5.9%
Q1 24
9.8%
10.9%
Capex Intensity
GYRE
GYRE
ISPR
ISPR
Q4 25
0.4%
0.3%
Q3 25
2.2%
0.0%
Q2 25
1.0%
4.8%
Q1 25
0.6%
0.7%
Q4 24
0.2%
0.1%
Q3 24
2.7%
0.7%
Q2 24
5.8%
2.0%
Q1 24
0.9%
0.3%
Cash Conversion
GYRE
GYRE
ISPR
ISPR
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons